Mativ expects leverage at upper end of 2.5x-3.5x by mid-2027 as Q4 adjusted EBITDA moderates low single-digit %

The Quick Take
Read the full report from the original publisher.
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to Seeking Alpha Market Currents.
Related
Markets
S&P 500 clings to 200-Day SMA as support zone comes into focus
Markets
Veracyte outlines 2027 view with ~10% volume growth and 22% adjusted EBITDA, while resetting Decipher prostate to 12,000-15,000 incremental tests
Markets
Profound Medical projects at least $25M 2026 revenue as Cook Medical channel ramps in 2027
Markets
Brent crude passes $100 amid Strait of Hormuz attacks - NewsBytes
Brent crude passes $100 amid Strait of Hormuz attacks NewsBytes
